×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT07170
clinical
1,431 words
KG: Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT07170150)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
topic:alzheimers-disease
topic:tau-immunotherapy
topic:brain-shuttle
Contents
Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT07170150)
Knowledge Graph
Related Hypotheses (14)
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
APOE Isoform Conversion Therapy
Score: 0.44
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Blood-Brain Barrier SPM Shuttle System
Score: 0.55
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Show 9 more
Related Analyses (4)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
See Also (15)
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 4 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Trace Amine-Associated Receptor (TAAR) Modulator Therap
therapeutic · Pages share 4 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 4 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 4 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapies for
therapeutic · Pages share 4 hypotheses
Somatostatin Receptor Modulator Therapy in Neurodegener
therapeutic · Pages share 4 hypotheses
Section 152: Advanced Robotics and Assistive Devices in
therapeutic · Pages share 4 hypotheses
Section 147: Telehealth and Remote Monitoring in CBS/PS
therapeutic · Pages share 4 hypotheses
S100 Protein (S100A8/A9/A12) Modulator Therapy for Neur
therapeutic · Pages share 4 hypotheses
RNA Targeting Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Progranulin Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
nt-3-therapy-neurodegeneration
therapeutic · Pages share 4 hypotheses
Neurotensin Receptor Modulator Therapy for Neurodegener
therapeutic · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (1 edges)
Trontinemab (RO7126209) Phase 3 Trial — TRONTIER 2 (NCT07170150)
references
GFAP